Fatih Demırkan
- Genetics top 2%
- Chronic Lymphocytic Leukemia Research 26
-
- Lymphoma Diagnosis and Treatment 22
- Hematology top 5%
- Chronic Myeloid Leukemia Treatments 14
- Multiple Myeloma Research and Treatments 13
- Acute Myeloid Leukemia Research 7
- Blood Coagulation and Thrombosis Mechanisms 6
- Hematopoietic Stem Cell Transplantation 6
- Immunology top 10%
- Immunodeficiency and Autoimmune Disorders 8
- Gastroenterology top 10%
- Co-authors
- Mehmet Ali ÖzcanCarol MorenoBülent ÜndarAlessandra TedeschiMartin ŠimkovičJohn G. GribbenRichard GreilDevinder Gill
- Journals
- Journal of Clinical Oncology (3 papers)SHILAP Revista de lepidopterología (4 papers)Blood (5 papers)
- Partner nations
- TürkiyeUnited StatesSpain
In The Last Decade
Fatih Demırkan
71 papers receiving 909 citations
Hit Papers
Peers
Comparison fields: 5 of 72
- Genetics 581
- Pathology and Forensic Medicine 489
- Hematology 302
- Immunology 220
- Gastroenterology 48
Countries citing papers authored by Fatih Demırkan
This map shows the geographic impact of Fatih Demırkan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fatih Demırkan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fatih Demırkan more than expected).
Fields of papers citing papers by Fatih Demırkan
This network shows the impact of papers produced by Fatih Demırkan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fatih Demırkan. The network helps show where Fatih Demırkan may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Fatih Demırkan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2022 | 3 | |
| 3 | 2022 | 0 | |
| 4 | 2021 | 1 | |
| 5 | 2021 | 9 | |
| 6 | 2021 | 8 | |
| 7 | Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trialbreakdown → | 2018 | 380 |
| 8 | 2018 | 3 | |
| 9 | 2018 | 2 | |
| 10 | IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY | 2016 | 4 |
| 11 | 2012 | 1 | |
| 12 | 2011 | 5 | |
| 13 | 2007 | 10 | |
| 14 | 2006 | 3 | |
| 15 | 2005 | 5 | |
| 16 | 2005 | 4 | |
| 17 | 2003 | 19 | |
| 18 | 2002 | 1 | |
| 19 | 2001 | 12 | |
| 20 | 2001 | 14 |
About Fatih Demırkan
Fatih Demırkan is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine, having authored 82 papers that have together received 926 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (26 papers), Lymphoma Diagnosis and Treatment (22 papers), Chronic Myeloid Leukemia Treatments (14 papers), Multiple Myeloma Research and Treatments (13 papers), Immunodeficiency and Autoimmune Disorders (8 papers), Acute Myeloid Leukemia Research (7 papers), Blood Coagulation and Thrombosis Mechanisms (6 papers) and Hematopoietic Stem Cell Transplantation (6 papers). The work is most often cited by research in Genetics (581 citations), Pathology and Forensic Medicine (489 citations) and Hematology (302 citations). Fatih Demırkan has collaborated with scholars based in Türkiye, United States and Spain. Frequent co-authors include Mehmet Ali Özcan, Carol Moreno, Bülent Ündar, Alessandra Tedeschi, Martin Šimkovič, John G. Gribben, Richard Greil, Devinder Gill, Bertrand Anz and Emily Hsu. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.